Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib + Standard Therapy in Newly Diagnosed KIT+ CBF-AML
NCT07028073Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of avapritinib in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started May 2025; status: recruiting.
02
Drugs
avapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07028073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028073.